menu
    • menu
    [{"orgOrder":0,"company":"Cerevance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Solengepras","moa":"G-protein coupled receptor 6 (GPR6)||GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cerevance \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Undisclosed"},{"orgOrder":0,"company":"Cerevance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Solengepras","moa":"G-protein coupled receptor 6 (GPR6)||GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevance \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Undisclosed"},{"orgOrder":0,"company":"Cerevance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Solengepras","moa":"G-protein coupled receptor 6 (GPR6)||GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevance \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Undisclosed"},{"orgOrder":0,"company":"Cerevance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Solengepras","moa":"G-protein coupled receptor 6 (GPR6)||GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerevance \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Undisclosed"},{"orgOrder":0,"company":"Cerevance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Solengepras","moa":"G-protein coupled receptor 6 (GPR6)||GPR6","graph1":"Undisclosed","graph2":"Phase I","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerevance \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cerevance \/ Undisclosed"},{"orgOrder":0,"company":"Cerevance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Solengepras","moa":"GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevance \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Undisclosed"},{"orgOrder":0,"company":"Cerevance","sponsor":"Agent Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"Solengepras","moa":"GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Cerevance \/ Agent Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Agent Capital"},{"orgOrder":0,"company":"Cerevance","sponsor":"Gates Frontier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"Solengepras","moa":"GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"Tablet","sponsorNew":"Cerevance \/ Gates Frontier","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Gates Frontier"},{"orgOrder":0,"company":"Cerevance","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series B Financing","leadProduct":"Solengepras","moa":"GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Cerevance \/ Google Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Google Ventures"},{"orgOrder":0,"company":"Cerevance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Solengepras","moa":"GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevance \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Undisclosed"},{"orgOrder":0,"company":"Cerevance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Solengepras","moa":"GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevance \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Solengepras

    Menu

    Solengepras

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cerevance Doses First Patient in Phase 3 ARISE Trial for Parkinson’s Disease

                            Details : CVN424 (solengepras) is a first-in-class non-dopamine therapy that selectively modulates GPR6, being investigated for the treatment option for individuals with early-stage Parkinson’s disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 18, 2024

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

                            Details : CVN424 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 14, 2024

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Agent Capital

                            Deal Size : $98.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline

                            Details : The financing is intended to support the clinical development of CVN424, which is being investigated as a treatment option for individuals with early-stage Parkinson’s disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 25, 2024

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Agent Capital

                            Deal Size : $98.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic T...

                            Details : CVN424 is a first-in-class non-dopamine therapy that selectively modulates GPR6, an orphan G-protein coupled receptor, which is investigated for the treatment option for individuals with early-stage Parkinson’s disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 13, 2023

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Early Parkinson's Disease Monotherapy With CVN424

                            Details : CVN424 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 23, 2023

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Gates Frontier

                            Deal Size : $116.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Cerevance Expands Series B Financing with Additional $51 Million

                            Details : The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis, and schizophrenia including CVN424, a first-in-class, oral, brain penetrant, non-dopaminergic, GPR6 inverse agonist in Phase 2 trial for ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 13, 2023

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Gates Frontier

                            Deal Size : $116.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Relative Bioavailability and Food Effect Study of CVN424

                            Details : CVN424 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 02, 2022

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson's Disease Drug Working Thro...

                            Details : CVN424 showed a 1.3-hour improvement in OFF time compared to placebo (p=0.042) at four weeks. This was accompanied by an increase in ON time without Troublesome Dyskinesia, without a meaningful worsening of ON time with Troublesome Dyskinesia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Google Ventures

                            Deal Size : $45.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Gates, GV Chip into $45M Round for CNS biotech Cerevance

                            Details : The proceeds will advance the company's lead Parkinson's disease plan into phase 2 and move other prospects into the clinic from earlier stages.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 14, 2020

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Google Ventures

                            Deal Size : $45.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

                            Details : CVN424 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 10, 2019

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth